ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc (TCON)

1.43
0.00
(0.00%)
Closed November 04 3:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.43
Bid
1.05
Ask
1.14
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.43
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
3,407,564
Dividend Yield
-
PE Ratio
-1.36
Earnings Per Share (EPS)
-1.05
Revenue
12.05M
Net Profit
-3.59M

About TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to de... TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, TJ4309, Bispecific Antibodies. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-

TCON Latest News

TRACON Pharmaceuticals Announces it Will Wind Down Operations

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision...

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SPPLSIMPPLE Ltd
US$ 1.18
(268.75%)
401.72M
NUWENewellis Inc
US$ 2.80
(105.88%)
100.16M
ADNAdvent Technologies Holdings Inc
US$ 3.34
(75.79%)
66.85M
STAFStaffing 360 Solutions Inc
US$ 2.8301
(66.48%)
53.1M
OMICSingular Genomics Systems Inc
US$ 22.28
(65.53%)
323.91k
TOIIWOncology Institute Inc
US$ 0.0101
(-47.67%)
58.23k
SSPEW Scripps Company
US$ 2.2701
(-35.51%)
4.27M
GCTKGlucoTrack Inc
US$ 1.15
(-33.91%)
82.44k
ILLRTriller Group Inc
US$ 2.86
(-33.18%)
2.33M
FGFFundamental Global Inc
US$ 15.2501
(-31.46%)
211.15k
SPPLSIMPPLE Ltd
US$ 1.18
(268.75%)
401.72M
ELABElevai Labs Inc
US$ 0.0202
(-30.10%)
290.65M
NVDANVIDIA Corporation
US$ 136.05
(0.48%)
187.52M
SQQQProShares UltraPro Short QQQ
US$ 7.52
(1.08%)
167.3M
DJTTrump Media and Technology Group Corporation
US$ 34.34
(12.37%)
120.92M

TCON Discussion

View Posts
willlbone willlbone 3 months ago
Layoffs, Liquidation.
๐Ÿ‘๏ธ0
davidsson10 davidsson10 4 months ago
https://www.globenewswire.com/news-release/2024/07/01/2906758/10391/en/TRACON-Pharmaceuticals-Announces-Termination-of-ENVASARC-Trial-and-Will-Explore-Strategic-Alternatives-Leveraging-its-In-House-Product-Development-Platform.html
๐Ÿ‘๏ธ0
Renee Renee 4 months ago
TCON delisted from the Nasdaq to the OTC. PPS dropped from $1.77 to $1.09

https://otce.finra.org/otce/dailyList?viewType=Additions
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
TCON new 52 week low
๐Ÿ‘๏ธ0
Gizzer211 Gizzer211 6 months ago
Old
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
TCON under $2
๐Ÿ‘๏ธ0
Renee Renee 7 months ago
TCON: effective April 10,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
๐Ÿ‘๏ธ0
kojak007 kojak007 7 months ago
ya thats my thought too. Thanks, all the best
๐Ÿ‘๏ธ0
Tartiaboy Tartiaboy 7 months ago
I liquidated my position in TCON on the news. I don't see a path forward for TCON that is good for current shareholders. I will monitor TCON going forward from the sidelines.
๐Ÿ‘๏ธ0
kojak007 kojak007 7 months ago
Hi Tartia,
I have no idea how this is possible. I guess its dead now. What do you think?

๐Ÿ‘๏ธ0
axelvento axelvento 7 months ago
With a float of 26 million shares and a market cap of $23 million, TRACON operates within the realm of oncology research and development. Envafolimab, one of TRACONโ€™s key assets, has garnered both Fast Track Designation and Orphan Drug Designation. Envafolimab, a novel PD-L1 antibody, is administered via subcutaneous injection, offering a convenient treatment approach.

The pivotal Phase 3 trial for Envafolimab, known as ENVASARC, is anticipated to provide updated safety and efficacy data by the end of the first quarter of 2024, with final data expected in the second half of the same year. The study design, presented at the American Society of Clinical Oncology (ASCO) in the previous year, outlines primary endpoints focused on objective response rate (ORR) confirmed by independent central review. The trial aims to assess Envafolimabโ€™s efficacy, particularly in refractory undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) patients, with an ORR confirmed by BICR with 9/80 objective responses needed to exclude the known < 5% ORR of pazopanib, the only agent approved for patients with refractory UPS or MFS.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 8 months ago
TCON..................................https://stockcharts.com/h-sc/ui?s=TCON&p=W&b=5&g=0&id=p86431144783
👍️ 1
Zardiw Zardiw 8 months ago
$TCON Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
๐Ÿ‘๏ธ0
Covid19freak Covid19freak 8 months ago
TCON $0.25 -interin data readout coming within days - market cap only $10 million
๐Ÿ‘๏ธ0
Covid19freak Covid19freak 8 months ago
TCON $0.24 with buy rating check out link below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
๐Ÿ‘๏ธ0
oldstocks oldstocks 9 months ago
Nice to see these Pharmaceuticals go up today!
TCON up 15.38% regular trading close
JAGX hit .1362 in after hours, up from .1027 open
ATNM up 2.95%

52 week highs:
TCON $2.19
JAGX $5.08
ATNM $14.70
๐Ÿ‘๏ธ0
TJG TJG 9 months ago
I only own AMRN and JAGX as my small cap ones. But am watching Tracon as I think they will get another order like the previous one that shot them up.
๐Ÿ‘๏ธ0
oldstocks oldstocks 9 months ago
TCON needs to be over $1.124 by March 7th

To do that there has to be some good exciting news releases from now and then. The news would have to be so good that shorts would all want to cover.
The higher the stock runs the better chance it stays on NASDAQ

A reverse split is not going to get it there because there would be too few of outstanding shares.



As previously reported, on June 8, 2023, TRACON Pharmaceuticals, Inc. (the โ€œCompanyโ€) received notices (the โ€œNoticesโ€) from Listing Qualifications staff of the Nasdaq Stock Market LLC (โ€œNasdaqโ€) notifying the Company that (i) for 30 consecutive business days preceding the date of the Notices, the market value of the Companyโ€™s common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the โ€œMarket Value Ruleโ€) and the Company did not meet any of the alternative continued listing requirements set forth in Nasdaq Listing Rule 5550(b) (the โ€œFinancial and Liquidity Standardsโ€), and (ii) for 30 consecutive business days preceding the date of the Notices, the closing bid price of the Companyโ€™s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the โ€œMinimum Bid Price Requirementโ€). The Company was provided 180 calendar days, or until December 5, 2023, to regain compliance with one of the Financial and Liquidity Standards and the Minimum Bid Price Requirement.

On December 12, 2023, the Company submitted a request for an oral appeal hearing before a Hearings Panel (the โ€œPanelโ€). The hearing is scheduled to occur on March 7, 2024. Accordingly, the delisting and suspension of trading of the Companyโ€™s common stock described in the December 6 Notice will be stayed pending the issuance of the Panelโ€™s final written decision. There can be no assurance that a favorable decision will be obtained from the Panel or that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Capital Market.
๐Ÿ‘๏ธ0
oldstocks oldstocks 10 months ago
TJ are you out of all stocks now?
I was just looking back at the old 8k's here.
I think this may have a chance for some news soon and maybe another spike but what do i know?
I can't predict news............
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
But the pre market has ended and the open market is not that impressed...
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Big news out having a great pre market day
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Nice day so far hopefully it holds these gains
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Thats the goal... get settled back in at a dollar and then let all hell break loses...
๐Ÿ‘๏ธ0
oldstocks oldstocks 11 months ago
It would be nice to see this get over $1
👍️ 1
YankeMike YankeMike 11 months ago
Yes, thanks. Good luck to us
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Closed at .21 in after hours hopefully some news drops tomorrow. Nice buy you have as well. Another 3 million dollar contract drops and this will move by leaps and bounds.
๐Ÿ‘๏ธ0
YankeMike YankeMike 11 months ago
Still have my shares I bought at $0.185 last week. Nice action today!
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Hell of a lot of ASK slapping today.... raise your hand if you joined me in buying those17 at the end of last week and the start of this week... The rest of you just grab a Puffs Plus
👍️ 1
TJG TJG 11 months ago
Market it still creating a buying opp, there are a lot of folks that have not read the 8-K on this last $3,000,000.00 up front payment deal... a $20 a share Pharma company is not small potatoes and for them to want this product speaks volumes. Lots more to come based on just this one deal. So thanks for the cheapies who ever it was that pushed this down to the 17's


https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92608567/form-8-k-current-report
👍️ 1
oldstocks oldstocks 11 months ago
TJ.. i posted this yesterday on another board
We bought TCON in hopes to make a profit.
I bought as high as .3089 and as low as .1862
I am not worried i am just waiting for the fluctuations. TCON is now heavily shorted.
They will have to buy back shares.

Tracon the company said it has licensed its proprietary PDP of CRO-independent clinical research to a clinical-stage biotech firm for a $3M upfront payment.

Latest news with Inhibrix is a big deal.

Under the deal, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical-stage biotech company for the design, conduct, and administration of clinical trials and related research and development activities, among others.
โ€œWe are now in a position to widely license our PDP to allow clinical-stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines,โ€ said CEO Charles Theuer.

About Inhibrix
Ticker INBX $20.54
$337 million in cash, so they have the money for the $3 Million deal.

https://inhibrx.com/wp-content/uploads/2023/11/Inhibrx-Presentation-Nov-2023.pdf

On November 17, 2023 (the โ€œEffective Dateโ€), Tracon Pharmaceuticals, Inc. (the โ€œCompanyโ€) entered into a License Agreement (the โ€œAgreementโ€) with Inhibrx, Inc. (โ€œInhibrxโ€). Under the terms of the Agreement, the Company granted a non-exclusive and non-transferable license of its product development platform to Inhibrx for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals (the โ€œTracon PDP Licenseโ€). The Tracon PDP License will allow Inhibrx to use the Companyโ€™s configuration documentation with a widely used software package in addition to use of the Companyโ€™s validation and qualification of the software package, and the Companyโ€™s standard operation procedure documents, policies, work instructions, and clinical operation templates (the โ€œLicensed Technologyโ€). Upon Inhibrxโ€™s request during the first six months after the Effective Date, the Company is obligated to provide up to 500 hours of training (โ€œTechnical Supportโ€) to Inhibrx. Pursuant to the Agreement, Inhibrx will make an upfront payment of $3.0 million to the Company, plus a potential $0.2 million (i) upon the completion of the Technical Support by the Company, or (ii) six months following the Companyโ€™s delivery of the Licensed Technology, whichever is earlier.
๐Ÿ‘๏ธ0
YankeMike YankeMike 11 months ago
Thanks for the info
👍️ 1
TJG TJG 11 months ago
Not sure how many have seen the 8 K that was filed to go along with the PR on the $3,000,000 contract but this is the company that bought the PDL licensee from TRACON Pharmaceuticals Inc. They are a $20.00 a share NASDAQ stock. This is not a micro cap Pinksheet stock its a $900 million dollar market cap company.

https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92608567/form-8-k-current-report

https://inhibrx.com/investors/
๐Ÿ‘๏ธ0
Copilotdog Copilotdog 11 months ago
Charles will split and dilute. Heโ€™s a pos.
๐Ÿ‘๏ธ0
oldstocks oldstocks 11 months ago
I just bought more before after market close.
Never know which direction this could go from here.
To cheap at this level.
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Good thing about Etrade is you can put a pre market order in and it will stall all day and up till 8 pm if you so choose...
๐Ÿ‘๏ธ0
oldstocks oldstocks 11 months ago
I had a buy order in the 17's in the AM market and I wasn't following it and the order automatically expired when the regular market opened
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Some Thanksgiving selling, very typical with this level of stocks...also a very nice buying opp for those that can see past two or three days in advance... doubled my holdings in those 17's which was just where my original buy in was.
๐Ÿ‘๏ธ0
oldstocks oldstocks 11 months ago
The 8am had a little spike and pulled back.
I am not worried about price decline.
It tends to pop later or another day.
๐Ÿ‘๏ธ0
TJG TJG 11 months ago
Well pre market is not doing us any favors down over 2 cents so far and we have yet to hit the real premarket trading which starts at 8 am

Most likely are good buying opp will come out of this morning
๐Ÿ‘๏ธ0
81vette 81vette 11 months ago
Lots of vol pre-mkt,could see gap up if hc wainwright paid promo shares are finally gone,(that analyst co is horrible,they shouldnโ€™t be able to call themselves analysts,all they do is put $7 on everything and get tons of shares and dump them until gone)
๐Ÿ‘๏ธ0
YankeMike YankeMike 11 months ago
Yes, it looks promising!
๐Ÿ‘๏ธ0
rayank rayank 11 months ago
A lot in the pipeline: "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Companyโ€™s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Companyโ€™s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States."
smile
👍️ 2
rayank rayank 11 months ago
Volume(Heavy Day) 73,872,965 November 21, 2023 3:59pm ET
👍️ 1
81vette 81vette 11 months ago
$15m traded today,gaining enough interest to have a sleepover for me
👍️ 1
81vette 81vette 11 months ago
Big orders slapping,some $15k,inst./whales?,gotta love big solid green candles as power hour approaches
👍️ 1
81vette 81vette 11 months ago
30% institutional,inst. controls 80% of entire mkt moves.follow the $ is a saying for a good reason.I doubt the blackrock crooked mms gonna destroy this,I could be wrong but it is optionable,contracts can suck for retail,holding up great so far and huge short to cover yet.support yesterday was sma200(5min) currently.1834 we getting close now
๐Ÿ‘๏ธ0
81vette 81vette 11 months ago
7m cash on hand,only 1m debt,no offering needed,1st of many contracts,3m contract on a 5m mkt cap,adjustment inbound,pps headed over $1 so no r/s needed.
๐Ÿ‘๏ธ0
81vette 81vette 11 months ago
TCON biz model is genius,during a gold rush sell pics/axes/shovels/maps/teach ppl how to pan,guarantee $ in bank!!
👍️ 1
81vette 81vette 11 months ago
Expect mid day vol surge soon
๐Ÿ‘๏ธ0
Wallstveteran Wallstveteran 11 months ago
tcon featured in article!
https://stockmarketcoffee.com/top-3-hottest-stocks-trading-today-under-5/
👍️ 1 🤑 1